中银晨会聚焦-20250730

Core Insights - The report highlights the ongoing trend of Chinese concept stocks returning to the domestic market, driven by policy guidance and market demand [5] - The healthcare sector is expected to see a revaluation opportunity as the National Healthcare Security Administration (NHSA) emphasizes anti-involution principles in drug procurement [8][10] Group 1: Strategy Research - The return of Chinese concept stocks is facilitated by a favorable regulatory environment, including the registration system and CDR (Chinese Depository Receipts) [5][6] - Various pathways for return include secondary listings in Hong Kong and privatization followed by IPOs in A-shares or Hong Kong [5][6] - The shell company market is experiencing a revaluation as demand for return increases, presenting investment opportunities [6][7] Group 2: Healthcare Sector - The NHSA has initiated the 11th batch of drug procurement, focusing on stabilizing prices and improving the procurement rules [9][10] - The previous procurement methods led to low pricing and affected profitability; however, the new measures are expected to enhance the profitability of pharmaceutical companies [9][10] - The pharmaceutical sector is gradually recovering from the impacts of procurement policies, with an optimistic outlook for revaluation as policies improve and companies' R&D efforts yield results [10]